Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVRONASDAQ:CDTXNASDAQ:CMPXNASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsCDTXCidara Therapeutics$21.31-3.6%$22.15$10.14▼$28.42$267.37M0.7988,702 shs127,800 shsCMPXCompass Therapeutics$2.38+8.7%$2.05$0.77▼$4.08$329.11M1.41952,958 shs765,396 shsSLDBSolid Biosciences$4.65+0.9%$3.42$2.41▼$10.37$360.45M2.221.16 million shs1.07 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVROAVROBIO0.00%0.00%0.00%0.00%-91.78%CDTXCidara Therapeutics0.00%-12.16%-20.78%-5.16%+76.12%CMPXCompass Therapeutics0.00%-1.24%+13.33%+3.03%+112.50%SLDBSolid Biosciences0.00%+1.53%+57.63%+1.09%-31.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVROAVROBION/AN/AN/AN/AN/AN/AN/AN/ACDTXCidara Therapeutics4.1521 of 5 stars4.62.00.04.62.50.00.0CMPXCompass Therapeutics3.5602 of 5 stars4.61.00.00.02.65.00.0SLDBSolid Biosciences3.4372 of 5 stars4.63.00.00.02.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVROAVROBIO 0.00N/AN/AN/ACDTXCidara Therapeutics 3.11Buy$42.86101.11% UpsideCMPXCompass Therapeutics 3.11Buy$13.13451.47% UpsideSLDBSolid Biosciences 3.23Buy$14.90220.43% UpsideCurrent Analyst Ratings BreakdownLatest AVRO, CMPX, SLDB, and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$41.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/10/2025CDTXCidara TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/6/2025SLDBSolid BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.006/4/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $36.006/2/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$47.005/27/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$47.005/23/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.00 ➝ $35.005/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVROAVROBION/AN/AN/AN/A$2.13 per shareN/ACDTXCidara Therapeutics$1.27M210.58N/AN/A$14.92 per share1.43CMPXCompass Therapeutics$850K387.18N/AN/A$0.91 per share2.62SLDBSolid Biosciences$8.09M44.55N/AN/A$3.43 per share1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVROAVROBIO$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/ACDTXCidara Therapeutics-$169.83M-$29.47N/AN/AN/AN/A-73.04%-54.28%8/12/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)Latest AVRO, CMPX, SLDB, and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVROAVROBION/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVROAVROBION/A26.1726.17CDTXCidara TherapeuticsN/A3.873.87CMPXCompass TherapeuticsN/A8.338.33SLDBSolid BiosciencesN/A10.8910.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVROAVROBIO62.63%CDTXCidara Therapeutics35.82%CMPXCompass Therapeutics68.43%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipAVROAVROBIO9.20%CDTXCidara Therapeutics3.89%CMPXCompass Therapeutics29.80%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVROAVROBIO1344.89 million40.76 millionOptionableCDTXCidara Therapeutics9012.55 million12.06 millionNo DataCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableSLDBSolid Biosciences10077.51 million76.04 millionOptionableAVRO, CMPX, SLDB, and CDTX HeadlinesRecent News About These CompaniesSolid Biosciences' (SLDB) Buy Rating Reaffirmed at HC WainwrightJune 19 at 1:27 AM | americanbankingnews.comSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesJune 18 at 11:39 AM | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC WainwrightJune 17 at 8:34 AM | marketbeat.comSolid Biosciences Approves Equity Plan Amendment at MeetingJune 13, 2025 | tipranks.comAnalysts Offer Predictions for SLDB FY2026 EarningsJune 11, 2025 | americanbankingnews.comBrokers Offer Predictions for SLDB FY2026 EarningsJune 10, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Two Sigma Investments LPJune 9, 2025 | marketbeat.comSolid Biosciences' (SLDB) "Market Outperform" Rating Reiterated at JMP SecuritiesJune 6, 2025 | marketbeat.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest UpdateJune 3, 2025 | marketbeat.comMillennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)June 1, 2025 | marketbeat.comSolid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthroughMay 28, 2025 | investing.comSolid Biosciences to Participate at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by BrokeragesMay 28, 2025 | marketbeat.comResearch Analysts Set Expectations for SLDB FY2025 EarningsMay 27, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor FitzgeraldMay 24, 2025 | marketbeat.comChardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock PriceMay 21, 2025 | marketbeat.comQ1 Earnings Forecast for SLDB Issued By William BlairMay 21, 2025 | marketbeat.comTruist maintains buy on Solid Biosciences stock, price target at $16May 18, 2025 | investing.comWhen Might Solid Biosciences Run Out Of Money?May 17, 2025 | finance.yahoo.comSolid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 16, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesAVRO, CMPX, SLDB, and CDTX Company DescriptionsAVROBIO NASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Cidara Therapeutics NASDAQ:CDTX$21.31 -0.79 (-3.57%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$21.30 -0.01 (-0.04%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Compass Therapeutics NASDAQ:CMPX$2.38 +0.19 (+8.68%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.43 +0.05 (+2.10%) As of 06/18/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Solid Biosciences NASDAQ:SLDB$4.65 +0.04 (+0.87%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.83 +0.18 (+3.87%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
